Day Two

• Identifying and validating target orthologs in mice to ensure accurate immuneoncology efficacy studies
• Employing syngeneic and xenograft mouse models and organoid systems to study tumour growth and immune response dynamics
• Linking the data from these models to elucidate the mode of action of vaccines and guide translational strategies

• Discussing the rationale behind applying orthotopic xenograft models to empower small molecule development to better treat glioblastoma
• Demonstrating potent anti-tumour activity of this small molecule in multiple glioblastoma models with strong blood-brain barrier penetration and favourable safety in toxicology studies
• Leveraging these preclinical findings to build a strong IND package and begin treating patients with high unmet medical need with the hope of better understanding the translational relevance of these models

Witness some of the latest and greatest research in the tumour modelling field in this spotlight

poster session! Check out the website for T&Cs.

• Understanding the rationale behind selecting the tumour models that were employed to aid the development of ADCs
• Overcoming the challenges with uncovering the therapeutic potential of the candidate to ensuring its effective translation to the clinic

• Integration of transcriptomics, organoid platforms, and in vivo regeneration and tumour models to study the relationship between tissue repair and tumour development
• Use of spatial transcriptomics and in vivo tumour modelling to reveal hidden cellular dynamics and link experimental findings to patient data
• Consideration of the translational relevance of these models and their implications for future research

• How will the new roadmaps encouraging non-animal tests from the FDA, and the UK affect your tumour model selection?
• How do you manage investor and senior-level expectations following these changes?
• Will investors continue to ask for in vivo/NHP data, or will their requirements change?

• Spotlighting the development of predictive preclinical resistance models
• Uncovering mechanistic insights into intrinsic and acquired resistance pathways
• Dissecting efficacy and linker properties using these models to improve the clinical translatability of ADC therapies

• Revealing CD270 as a key melanoma escape mechanism through tumour‑model–driven studies demonstrating that high CD270 expression is mutually exclusive with PD‑L1 and strongly associated with resistance to PD‑1/PD‑L1 inhibitors
• Demonstrating robust immunostimulatory activity of JJP‑1008 in in vitro models and humanized melanoma models (CDX/NOG), where repeated dosing inhibited aggressive tumour growth, reduced cachexia, and increased CD4⁺/CD8⁺ T‑cell infiltration—shifting the microenvironment from immunosuppression to activation
• Elucidating JJP‑1008’s selective blockade of immunosuppressive HVEM signals (BTLA/CD160) while preserving LIGHT‑mediated co‑stimulation, offering a novel mechanism to restore antitumour immunity and enhance model‑based evaluation of next‑generation immunotherapies